Newly appreciated therapeutic effect of GLP-1 receptor agonists: Reduction in postprandial lipemia

Atherosclerosis

Volumn 212, Issue 1, 2010, Pages 40-41

  Bandsma, Robert H J ^a   Lewis, Gary F ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B100; APOLIPOPROTEIN B48; CHYLOMICRON; EXENDIN 4; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; HEMOGLOBIN A1C; INCRETIN; INSULIN; PLACEBO; SITAGLIPTIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN; VILDAGLIPTIN;

ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; CHRONIC DRUG ADMINISTRATION; CLINICAL TRIAL; COMPETITIVE INHIBITION; CONCENTRATION (PARAMETERS); DRUG COST; HUMAN; HYPERLIPIDEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN RELEASE; INSULIN RESISTANCE; LIPID METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NOTE; OBESITY; PANCREAS ISLET BETA CELL; POSTPRANDIAL STATE; PRIORITY JOURNAL; SINGLE DRUG DOSE; THERAPY EFFECT;

APOLIPOPROTEIN B-48; APOLIPOPROTEIN C-III; BIOLOGICAL MARKERS; BLOOD GLUCOSE; CHOLESTEROL; DIABETES MELLITUS, TYPE 2; DIETARY FATS; FATTY ACIDS, NONESTERIFIED; HUMANS; HYPERLIPIDEMIAS; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; INSULIN; LIPOPROTEINS; PEPTIDES; POSTPRANDIAL PERIOD; RECEPTORS, GLUCAGON; TIME FACTORS; TREATMENT OUTCOME; TRIGLYCERIDES; VENOMS;

EID: 77956230171     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2010.06.033     Document Type: Note

References (15)

1. Lewis G.F. Postprandial lipoprotein metabolism in diabetes mellitus and obesity. J Atheroscler Thromb 1995, 2(Suppl. 1):S34-S35.
2. Adeli K., Lewis G.F. Intestinal lipoprotein overproduction in insulin-resistant states. Curr Opin Lipidol 2008, 19:221-228.
3. Drucker D.J. The biology of incretin hormones. Cell Metab 2006, 3:153-165.
4. Drucker D.J., Nauck M.A. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006, 368:1696-1705.
5. Qin X., Shen H., Liu M., et al. GLP-1 reduces intestinal lymph flow, triglyceride absorption, and apolipoprotein production in rats. Am J Physiol Gastrointest Liver Physiol 2005, 288:G943-G949.
6. Hsieh J., Longuet C., Baker C.L., et al. The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice. Diabetologia 2010, 53:552-561.
7. Schwartz S.L., Ratner R.E., Kim D.D., et al. Effect of exenatide on 24-hour blood glucose profile compared with placebo in patients with type 2 diabetes: a randomized, double-blind, two-arm, parallel-group, placebo-controlled, 2-week study. Clin Ther 2008, 30:858-867.
8. DeFronzo R.A., Okerson T., Viswanathan P., et al. Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study. Curr Med Res Opin 2008, 24:2943-2952.
9. Matikainen N., Manttari S., Schweizer A., et al. Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes. Diabetologia 2006, 49:2049-2057.
10. Meier J.J., Gethmann A., Gotze O., et al. Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans. Diabetologia 2006, 49:452-458.
11. Schwartz E.A., Koska J., Mullin M.P., et al. Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus. Atherosclerosis 2010, 212:217-222.
12. Meier J.J., Gallwitz B., Salmen S., et al. Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes. J Clin Endocrinol Metab 2003, 88:2719-2725.
13. Tolessa T., Gutniak M., Holst J.J., et al. Glucagon-like peptide-1 retards gastric emptying and small bowel transit in the rat: effect mediated through central or enteric nervous mechanisms. Dig Dis Sci 1998, 43:2284-2290.
14. Parlevliet E.T., Schroder-van der Elst J.P., Corssmit E.P., et al. CNTO736, a novel glucagon-like peptide-1 receptor agonist, ameliorates insulin resistance and inhibits very low-density lipoprotein production in high-fat-fed mice. J Pharmacol Exp Ther 2009, 328:240-248.
15. Pavlic M., Xiao C., Szeto L., et al. Insulin acutely inhibits intestinal lipoprotein secretion in humans in part by suppressing plasma free fatty acids. Diabetes 2010, 59:580-587.